Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPIRE-1
2026-525684-40-01Phase 2Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in chronic kidney disease (CKD) and diabetes mellitus type 1 (T1D) comparing SC0062 alone, dapagliflozin alone and SC0062 + dapagliflozin (3 arms). Primary endpoint: Change from baseline in urine albumin-creatinine ratio. Planned start Oct 2026; status: authorised.
02
Drugs
SC0062dapagliflozin
03
Conditions
chronic kidney disease (CKD)diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2026-525684-40-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525684-40-01.